Pneumococcal serotype diversity among adults in various countries, influenced by pediatric pneumococcal vaccination uptake

Clinical Infectious Diseases

Volumn 58, Issue 6, 2014, Pages 854-864

  Grabenstein, John D ^a   Weber, David J ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

epidemiology; pneumococcal infections; pneumococcal vaccines; serotyping; Streptococcus pneumoniae

Indexed keywords

PNEUMOCOCCUS VACCINE; 23-VALENT PNEUMOCOCCAL CAPSULAR POLYSACCHARIDE VACCINE; PREVENAR13; VACCINE;

ARTICLE; AUSTRALIA; FRANCE; HUMAN; INCIDENCE; MICROBIAL DIVERSITY; NEW ZEALAND; NONHUMAN; PNEUMOCOCCAL INFECTION; PORTUGAL; PRIORITY JOURNAL; SEROTYPE; STREPTOCOCCUS PNEUMONIAE; UNITED KINGDOM; UNITED STATES; VACCINATION; ADOLESCENT; ADULT; AGED; CHILD; CLASSIFICATION; IMMUNOLOGY; MICROBIOLOGY; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PRESCHOOL CHILD; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; HUMANS; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; STREPTOCOCCUS PNEUMONIAE; VACCINES, CONJUGATE; YOUNG ADULT;

EID: 84895780775     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit800     Document Type: Article

References (74)

1. Calix JJ, Porambo RJ, Brady AM, et al. Biochemical, genetic, and serological characterization of two capsule subtypes among Streptococcus pneumoniae serotype 20 strains: discovery of a new pneumococcal serotype. J Biol Chem 2012; 287:27885-94.
2. Sjöström K, Spindler C, Ortqvist A, et al. Clonal and capsular types decide whether pneumococci will act as a primary or opportunistic pathogen. Clin Infect Dis 2006; 42:451-9.
3. Jansen AG, Rodenburg GD, van der Ende A, et al. Invasive pneumococcal disease among adults: associations among serotypes, disease characteristics, and outcome. Clin Infect Dis 2009; 49:e23-9.
4. Bewick T, Sheppard C, Greenwood S, et al. Serotype prevalence in adults hospitalised with pneumococcal non-invasive communityacquired pneumonia. Thorax 2012; 67:540-5.
5. van Hoek AJ, Andrews N, Waight PA, et al. Effect of serotype on focus and mortality of invasive pneumococcal disease: coverage of different vaccines and insight into non-vaccine serotypes. PLoS One 2012; 7: e39150.
6. Song JY, Nahm MH, Moseley MA. Clinical implications of pneumococcal serotypes: invasive disease potential, clinical presentations, and antibiotic resistance. J Korean Med Sci 2013; 28:4-15.
7. Harboe ZB, Thomsen RW, Riis A, et al. Pneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study. PLoS Med 2009; 6:e1000081.
8. Weinberger DM, Harboe ZB, Sanders EA, et al. Association of serotype with risk of death due to pneumococcal pneumonia: a meta-analysis. Clin Infect Dis 2010; 51:692-9.
9. Feikin DR, Klugman KP. Historical changes in pneumococcal serogroup distribution: implications for the era of pneumococcal conjugate vaccines. Clin Infect Dis 2002; 35:547-55.
10. Hicks LA, Harrison LH, Flannery B, et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J Infect Dis 2007; 196:1346-54.
11. European Centre for Disease Prevention and Control. Surveillance of invasive pneumococcal disease in Europe, 2010. Stockholm: ECDC, 2012. Available at: http://www.ecdc.europa.eu/en/publications/publications/ invasive- pneumoccocal-disease-surveillance-2010.pdf. Accessed 14 November 2013.
12. Fedson DS, Nicolas-Spony L, van der Linden M, et al. Pneumococcal polysaccharide vaccination for adults: new perspectives for Europe. Expert Rev Vaccines 2011; 10:1143-67.
13. Pilishvili T, Lexau C, Farley MM, et al.; Active Bacterial Core Surveillance/ Emerging Infections Program Network. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010; 201:32-41.
14. Hausdorff WP, Feikin DR, Klugman KP. Epidemiological differences among pneumococcal serotypes. Lancet Infect Dis 2005; 5:83-93.
15. Cobey S, Lipsitch M. Niche and neutral effects of acquired immunity permit coexistence of pneumococcal serotypes. Science 2012; 335: 1376-80.
16. Norton NB, Stanek RJ, Mufson MA. Routine pneumococcal vaccination of children provokes new patterns of serotypes causing invasive pneumococcal disease in adults and children. Am J Med Sci 2013; 345: 112-120.
17. Advisory Committee on Immunization Practices. Pneumococcal polysaccharide vaccine. MMWR Morb Mort Wkly Rep 1978; 27:25-6, 31.
18. Hilleman MR, Carlson AJ Jr, McLean AA, et al. Streptococcus pneumoniae polysaccharide vaccine: age and dose responses, safety, persistence of antibody, revaccination, and simultaneous administration of pneumococcal and influenza vaccines. Rev Infect Dis 1981; 3(suppl):S31-42.
19. Robbins JB, Austrian R, Lee CJ, et al. Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups. J Infect Dis 1983; 148:1136-59.
20. Advisory Committee on Immunization Practices. Pneumococcal polysaccharide vaccine usage - United States. MMWR Morb Mort Wkly Rep 1984; 33:273-6, 281.
21. Hausdorff WP, Bryant J, Paradiso PR, et al. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin Infect Dis 2000; 30:100-21.
22. Hausdorff WP, Bryant J, Kloek C, et al. The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II. Clin Infect Dis 2000; 30:122-40.
23. Song JH, Dagan R, Klugman KP, et al. The relationship between pneumococcal serotypes and antibiotic resistance. Vaccine 2012; 30:2728-37.
24. Grabenstein JD. Effectiveness and serotype coverage: key criteria for pneumococcal vaccines for adults. Clin Infect Dis 2012; 55:255-8.
25. Pedersen MK, Høiby EA, Frøholm LO, et al. Systemic pneumococcal disease in Norway 1995-2001: capsular serotypes and antimicrobial resistance. Epidemiol Infect 2004; 132:167-75.
26. Kyaw MH, Christie P, Clarke SC, et al. Invasive pneumococcal disease in Scotland, 1999-2001: use of record linkage to explore associations between patients and disease in relation to future vaccination policy. Clin Infect Dis 2003; 37:1283-91.
27. Thomas K, Kesavan LM, Veeraraghavan B, et al. IBIS Study Group IndiaCLEN Network. Invasive pneumococcal disease associated with high case fatality in India. J Clin Epidemiol 2013; 66:36-43.
28. Imöhl M, Reinert RR, van der Linden M. Regional differences in serotype distribution, pneumococcal vaccine coverage, and antimicrobial resistance of invasive pneumococcal disease among German federal states. Int J Med Microbiol 2010; 300:237-47.
29. Aguiar SI, Serrano I, Pinto FR, et al. Portuguese Surveillance Group for the Study of Respiratory Pathogens. Changes in Streptococcus pneumoniae serotypes causing invasive disease with non-universal vaccination coverage of the seven-valent conjugate vaccine. Clin Microbiol Infect 2008; 14:835-43.
30. Foster D, Knox K, Walker AS, et al.; Oxford Invasive Pneumococcal Surveillance Group. Invasive pneumococcal disease: epidemiology in children and adults prior to implementation of the conjugate vaccine in the Oxfordshire region, England. J MedMicrobiol 2008; 57(Pt 4):480-7.
31. Varon E, Janoir C, Gutmann L. Centre National de Référence des Pneumocoques: rapport d'activité 2012, epidémiologie 2011. Available at: www.invs.sante.fr/Espace-professionnels/Centres-nationaux- dereference/ Rapports-d-activites-et-liens. Accessed 14 November 2013.
32. Horácio AN, Diamantino-Miranda J, Aguiar SI, et al.; Portuguese Group for Study of Streptococcal Infections. Serotype changes in adult invasive pneumococcal infections in Portugal did not reduce the high fraction of potentially vaccine preventable infections. Vaccine 2012; 30:218-24.
33. Roche PW, Krause VL, Bartlett M, et al.; Pneumococcal Working Party of the Communicable Diseases Network Australia. Invasive pneumococcal disease in Australia, 2004. Commun Dis Intell Q Rep 2006; 30:80-92. Available at: www.health.gov.au/internet/main/publishing. nsf/Content/cda-cdi3001-pdf-cnt.htm/ $FILE/cdi3001b.pdf. Accessed 19 December 2013.
34. Barry C, Krause VL, Cook HM, et al. Invasive pneumococcal disease in Australia: 2007 and 2008. Comm Dis Intell 2012; 36:e151-65.
35. Heffernan HM, Martin DR, Woodhouse RE, et al. Invasive pneumococcal disease in New Zealand 1998-2005: capsular serotypes and antimicrobial resistance. Epidemiol Infect 2008; 136:352-9.
36. Lim E, Heffernan H. Invasive pneumococcal disease in New Zealand, 2012. Porirua: Institute of Environmental Science and Research Ltd, 2013. Available at: https://surv.esr.cri.nz/PDF-surveillance/IPD/2012/ 2012AnnualIPDRpt.pdf. Accessed 14 November 2013.
37. Advisory Committee on Immunization Practices. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb Mortal Wkly Rep 2010; 59:1102-6.
38. Inostroza J, Illesca V, Reydet P, et al. Ten-year surveillance of pneumococcal infections in Temuco, Chile: implications for vaccination strategies. Clin Vaccine Immunol 2007; 14:660-4.
39. Liesenborghs L, Verhaegen J, Peetermans WE, et al. Trends in serotype prevalence in invasive pneumococcal disease before and after infant pneumococcal vaccination in Belgium, 2002-2010. Vaccine 2013; 31:1529-34.
40. Motlova J, Benes C, Kriz P. Incidence of invasive pneumococcal disease in the Czech Republic and serotype coverage by vaccines, 1997-2006. Epidemiol Infect 2009; 137:562-9.
41. Klemets P, Lyytikäinen O, Ruutu P, et al. Trends and geographical variation in invasive pneumococcal infections in Finland. Scand J Infect Dis 2008; 40:621-8.
42. Vickers I, Fitzgerald M, Murchan S, et al. Serotype distribution of Streptococcus pneumoniae causing invasive disease in the Republic of Ireland. Epidemiol Infect 2011; 139:783-90.
43. Skoczyńska A, Sadowy E, Bojarska K, et al. Participants of laboratorybased surveillance of community acquired invasive bacterial infections (BINet). The current status of invasive pneumococcal disease in Poland. Vaccine 2011; 29:2199-205.
44. Ardanuy C, Marimón JM, Calatayud L, et al. Epidemiology of invasive pneumococcal disease in older people in Spain (2007-2009): implications for future vaccination strategies. PLoS One 2012; 7:e43619.
45. Kronenberg A, Zucs P, Droz S, et al. Distribution and invasiveness of Streptococcus pneumoniae serotypes in Switzerland, a country with low antibiotic selection pressure, from 2001 to 2004. J Clin Microbiol 2006; 44:2032-8.
46. Percin D, Ay Altintop Y, Sumerkan B. Ten-year surveillance of invasive Streptococcus pneumoniae isolates in central Turkey prior to the introduction of a conjugate vaccine. J Infect Dev Ctries 2010; 4:560-5.
47. Chiba N, Morozumi M, Sunaoshi K, et al., IPD Surveillance Study Group. Serotype and antibiotic resistance of isolates from patients with invasive pneumococcal disease in Japan. Epidemiol Infect 2010; 138:61-8.
48. Lee S, Bae S, Lee KJ, et al. Changes in serotype prevalence and antimicrobial resistance among invasive Streptococcus pneumoniae isolates in Korea, 1996-2008. J Med Microbiol 2013; 62:1204-10.
49. Hsieh YC, Lin PY, Chiu CH, et al. National survey of invasive pneumococcal diseases in Taiwan under partial PCV7 vaccination in 2007: emergence of serotype 19A with high invasive potential. Vaccine 2009; 27:5513-8.
50. Demczuk WH, Martin I, Griffith A, et al., Toronto Invasive Bacterial Diseases Network, Canadian Public Health Laboratory Network. Serotype distribution of invasive Streptococcus pneumoniae in Canada during the introduction of the 13-valent pneumococcal conjugate vaccine, 2010. Can J Microbiol 2012; 58:1008-17.
51. Miller E, Andrews NJ, Waight PA, et al. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis 2011; 11:760-8.
52. Trotter CL, Waight P, Andrews NJ, et al. Epidemiology of invasive pneumococcal disease in the pre-conjugate vaccine era: England and Wales, 1996-2006. J Infect 2010; 60:200-8.
53. Muhammad RD, Oza-Frank R, Zell E, et al. Epidemiology of invasive pneumococcal disease among high-risk adults since the introduction of pneumococcal conjugate vaccine for children. Clin Infect Dis 2013; 56: e59-67.
54. Kellner JD, Vanderkooi OG, MacDonald J, et al. Changing epidemiology of invasive pneumococcal disease in Canada, 1998-2007: update from the Calgary-area Streptococcus pneumoniae research (CASPER) study. Clin Infect Dis 2009; 49:205-12.
55. Grall N, Hurmic O, Al Nakib M, et al.; ORP Ile de France Ouest. Epidemiology of Streptococcus pneumoniae in France before introduction of the PCV-13 vaccine. Eur J Clin Microbiol Infect Dis 2011; 30:1511-9.
56. Lehmann D, Willis J, Moore HC, et al. The changing epidemiology of invasive pneumococcal disease in aboriginal and non-aboriginal western Australians from 1997 through 2007 and emergence of nonvaccine serotypes. Clin Infect Dis 2010; 50:1477-86.
57. Johnson DR, D'Onise K, Holland RA, et al. Pneumococcal disease in South Australia: vaccine success but no time for complacency. Vaccine 2012; 30:2206-11.
58. Public Health England. Cumulative weekly number of reports of invasive pneumococcal disease due to any of the six serotypes in Prevenar13 but not in PCV7: persons aged >=5 years in England and Wales by epidemiological year: July-June (2005-to date). Available at: http:// www.hpa.org.uk/Topics/ InfectiousDiseases/InfectionsAZ/Pneumococcal/ EpidemiologicalDataPneumococcal/ CurrentEpidemiologyPneumococcal/. Accessed 14 November 2013.
59. Moore MR. Update on effectiveness and impact of PCV13 use among U.S. children. Presentation to Advisory Committee on Immunization Practices, 23 October 2013. Available at: http://www.cdc.gov/vaccines/ acip/meetings/ downloads//slides-oct-2013/02-Pneumococcal-Moore.pdf. Accessed 14 November 2013.
60. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000; 19:187-95.
61. Hak E, Grobbee DE, Sanders EA, et al. Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults. Neth J Med 2008; 66:378-83.
62. ClinicalTrials.gov. Study evaluating a 13-valent pneumococcal conjugate vaccine (13vPnC) in adults (CAPITA). Available at: www.clinicaltrials. gov/ct2/show/NCT00744263. Accessed 14 November 2013.
63. Moberley SA, Holden J, Tatham DP, et al. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2013:1-79. doi:10.1002/14651858.CD000422.pub3.
64. Maruyama T, Taguchi O, Niederman MS, et al. Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: double blind, randomised and placebocontrolled trial. BMJ 2010; 340, c1004 (1-7).
65. Moore M, Link-Gelles R, Farley MM, et al. Impact of 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease, U.S., 2010-11. In: IDWeek, San Diego, CA, 17-21 October 2012. Abstract 1219. Available at: https://idsa.confex.com/idsa/2012/webprogram/ Paper36569.html. Accessed 16 May 2013.
66. Advisory Committee on Immunization Practices. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2012; 61:816-9. Available at: http://www.cdc.gov/mmwr/pdf/wk/mm6140.pdf. Accessed 19 December 2013.
67. Canadian National Advisory Committee on Immunization. Statement on the use of conjugate pneumococcal vaccine - 13 valent in adults (PNEU-C-13). Can Comm Dis Rep 2013; 39(ACS-5):1-52.
68. Joint Committee on Vaccination and Immunisation. JCVI statement on the wider use of pneumococcal conjugate vaccines in the UK, July 2013. Available at: https://www.gov.uk/government/uploads/system/ uploads/attachment-data/file/ 224765/JCVI-statement-on-pneumococcal- vaccination-for-clinical-risk-groups- Final.pdf. Accessed 14 November 2013.
69. Deutschland Standigen Impfkommission. Empfehlungen der Standigen Impfkommission (STIKO) am Robert Koch-Institut. Epidemiologisches Bulletin No. 34, 26 August 2013. Available at: www.rki.de/DE/ Content/Infekt/EpidBull/Archiv/ 2013/Ausgaben/34-13.pdf?-blob= publicationFile. Accessed 14 November 2013.
70. Deutschland Standigen Impfkommission. Stellungnahme zur Impfung Erwachsener gegen Pneumokokken. Epidemiologisches Bulletin No. 7, 20 February 2013. Available at: www.rki.de/DE/Content/Infekt/ EpidBull/Archiv/2012/Ausgaben/ 07-12.pdf?-blob=publicationFile. Accessed 14 November 2013.
71. Australia National Health and Medical Research Council. Australian immunisation handbook. 10th ed. Canberra: National Health & Medical Research Council, 2013. Available at: www.immunise.health. gov.au/internet/immunise/ publishing.nsf/Content/Handbook10-home. Accessed 19 December 2013.
72. Link-Gelles R, Taylor T, Moore MR, Active Bacterial Core Surveillance Team. Forecasting invasive pneumococcal disease trends after the introduction of 13-valent pneumococcal conjugate vaccine in the United States, 2010-2020. Vaccine 2013; 31:2572-7.
73. Sherwin RL, Gray S, Alexander R, et al. Distribution of 13-valent pneumococcal conjugate vaccine Streptococcus pneumoniae serotypes in US adults aged ≥50 years with community-acquired pneumonia. J Infect Dis 2013; 208:1813-20.
74. Rodrigo C, Bewick T, Sheppard C, et al. Pneumococcal serotypes in adult non-invasive and invasive pneumonia in relation to child contact and child vaccination status [epub ahead of print]. Thorax 2013. doi:10.1136/thoraxjnl- 2013-203987.